QUT offers a diverse range of student topics for Honours, Masters and PhD study. Search to find a topic that interests you or propose your own research topic to a prospective QUT supervisor. You may also ask a prospective supervisor to help you identify or refine a research topic.
Found 30 matching student topics
Displaying 1–12 of 30 results
Interactive art
This suggested practice-based research project seeks, overall, to ask how interactive art engages audiences, how it is created and, depending on the applicant's interest and expertise, how it might be a collaborative effort between artist and technologist.ituated within the nascent area of interactive art, contributing new understandings and research into the form and design of interactive art works; and new insights into audience experience of interactive art.The project can engage with themes and theories in its exploration of interactive art …
- Study level
- PhD, Master of Philosophy
- Faculty
- Faculty of Creative Industries, Education and Social Justice
- School
- School of Design
- Research centre(s)
-
Design Lab
Investigating the role of Neuropilin-1 in Triple-Negative Breast Cancer metastasis and chemoresistance
Triple-negative breast cancers (TNBC) are negative for Estrogen Receptor, Progesterone Receptor and HER2 expression, are clinically aggressive and are unresponsive to the available hormonal or targeted drugs used for other breast cancer subtypes, so that TNBC patients rely mainly on chemotherapy. TNBC accounts for 15-20% of all invasive breast cancer and patients have increased risk of recurrence, mortality and early metastatic progression. Thus, there is an urgent clinical need to develop improved treatment strategies for TNBC. Neuropilin-1 (NRP1) is a …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Testing a promising targeted therapeutic for triple-negative breast cancer
Triple-negative breast cancers (TNBC) are negative for Estrogen Receptor, Progesterone Receptor and HER2 expression, are clinically aggressive and cannot be treated with the available hormonal or targeted drugs used for other breast cancer subtypes. TNBC accounts for 15-20% of all invasive breast cancer and patients have increased risk of recurrence, mortality and metastases early during disease progression. There is an urgent clinical need to develop improved treatment strategies for these women since the median survival of patients with metastatic TNBC …
- Study level
- PhD, Master of Philosophy
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Characterisation of a novel protein co-amplified with the n-MYC oncogene
The MYCN oncogene is amplified in a number of tumour types, including Neuroblastoma (NB) and Neuroendocrine Prostate Cancer (NEPC), where it is associated with worse patient prognosis, as compared to non-amplified tumours. However, the high expression of MYCN (encoding the n-MYC protein) alone in non-amplified tumours is associated with better patient prognosis and less aggressive disease. This suggests that other genes co-expressed in MYCN amplified tumours may be responsible for mediating the aggressive traits of n-MYC. Our team has identified …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
- Centre for Genomics and Personalised Health
A novel molecular targeted therapy for anaplastic prostate cancer
In advanced PCa, where the cancer has spread into the bone and other organs, the emergence of treatment resistance remains inevitable. For decades the primary form of treatment in advanced PCa has been to target the production and actions of male sex hormones, androgens, the primary developmental and survival factor of prostate tissue. While these therapies result in tumour regression and cancer control, this is temporary and treatment resistance occurs, referred to as castrate resistant prostate cancer (CRPC). In the …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Developing a precision oncology workflow for Osteosarcoma treatment
Osteosarcoma (OS) is the most common malignant bone tumour that primarily affects children and adolescents. With approximately 400 diagnosed cases/year in Australia, OS has the lowest survival rate of all solid cancers and is the leading cause of cancer-related death in Queensland adolescents. Unfortunately, 3 in 4 patients will not survive longer than five years following diagnosis with metastatic OS. Clinical “one size fits all” treatment strategies results in highly variable and unacceptably poor patient responses. Shockingly, both the OS …
- Study level
- PhD, Master of Philosophy
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
- Centre for Biomedical Technologies
Reversing Epithelial Mesenchymal Plasticity with Eribulin to Enhance Therapy Response
Epithelial mesenchymal plasticity (EMP) is a highly regulated and powerful cellular process that is fundamental in embryonic development (1), which is hijacked by cancer cells for metastatic progression and therapy resistance in epithelial cancers (2). Eribulin is a microtubule-inhibiting cancer drug discovered in sea sponges and approved for 3rd line therapy in metastatic breast cancer, which was shown to reverse epithelial mesenchymal transition (EMT) (3).We hypothesise that eribulin’s reversal of EMT will sensitise breast cancer cells to other therapies and …
- Study level
- Master of Philosophy
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Targeting a novel adaptive neovascular response of the tumour microenvironment to treat advanced prostate cancer
Prostate cancer (PCa) is a significant healthcare burden in Australia. Androgen signalling inhibition using androgen receptor (AR) antagonists is the principal systemic therapy for advanced PCa. Androgen receptors (AR) are an attractive therapeutic target due to their elevated expression in tumour epithelial cells and the retention of androgen signalling throughout the disease continuum.However, patients eventually develop resistance to treatment, and PCa cells metastasise to distant bone and visceral organs, representing an incurable stage of the disease. Understanding mechanisms that contribute …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Eribulin effects on epithelial mesenchymal plasticity and therapy response
Epithelial mesenchymal plasticity (EMP) is a highly regulated and powerful cellular process that is fundamental in embryonic development (1), which is hijacked by cancer cells for metastatic progression and therapy resistance in epithelial cancers (2). Eribulin is a microtubule-inhibiting cancer drug discovered in sea sponges and approved for 3rd line therapy in metastatic breast cancer, which was shown to block EMP (3).We hypothesise that eribulin’s reversal of EMT will sensitise breast cancer cells to other therapies and ultimately improve patient …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Immunotherapy for autoimmune disease using T cell receptor-modified T-regulatory cells
Autoimmune diseases affect approximately 5% of Australians. Well known examples include type I diabetes, multiple sclerosis and rheumatoid arthritis. These diseases have unpleasant, and sometimes tragic, consequences for the affected person and are a costly burden on our health system. As treatment is often limited to managing symptoms, new therapies for autoimmune diseases are much desired.Many autoimmune diseases are tightly associated with inheritance of a particular allele at the major histocompatibility complex (MHC, also called human leucocyte antigen or HLA). …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Therapeutic opportunities targeting epigenetic-metabolism crosswalks in cancer
Epigenetic and metabolic pathways in cancer cells are highly interconnected. Epigenetic landscape in cancer cells is modified by oncogene-driven metabolic changes. Metabolites modulate the activities of epigenetic modifying enzymes to regulate the expression of specific genes. Conversely, epigenetic deregulation that occurs in cancer affect the expression of metabolic genes, thereby altering the metabolome. These changes all coordinately enhance cancer cell proliferation, metastasis and therapy resistance.The overall aim of the project is to understand the link between the activity of epigenetic …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Epigenetic regulation of non-coding RNAs in hypoxic tumours
In solid tumours, hypoxia occurs as a result of limitation on oxygen diffusion in avascular primary tumours or their metastases. Persistent hypoxia, significantly reduces the efficacy of radiation and chemotherapy and lead to poor outcomes. This is mainly due to increase in pro-survival genes that suppress apoptosis, enhance tumour angiogenesis, the epithelial-to-mesenchymal transition, invasiveness and metastasis. Much of tumour hypoxia research has been centred on examining the transcriptional targets of hypoxia inducible factors (HIFs).HypothesisEpigenetic changes mediate the effect of hypoxia …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Contact us
If you have questions about the best options for you, the application process, your research topic, finding a supervisor or anything else, get in touch with us today.